UBS AM
CDLX icon

UBS AM’s Cardlytics CDLX Stock Holding History

UBS AM’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,838
Closed -$280K – 2684
2022
Q4 		$280K Sell
4,838
-31
-0.6% -$1.92K ﹤0.01% 2352
2022
Q3 		$458K Buy
4,869
+558
+13% +$79.4K ﹤0.01% 2376
2022
Q2 		$962K Sell
4,311
-15
-0.3% -$5.02K ﹤0.01% 1989
2022
Q1 		$2.38M Buy
4,326
+529
+14% +$320K ﹤0.01% 1714
2021
Q4 		$2.51M Hold
3,797
– – ﹤0.01% 1766
2021
Q3 		$3.19M Hold
3,797
– – ﹤0.01% 1597
2021
Q2 		$4.82M Buy
3,797
+546
+17% +$616K ﹤0.01% 1385
2021
Q1 		$3.57M Buy
3,251
+301
+10% +$397K ﹤0.01% 1498
2020
Q4 		$4.21M Buy
2,950
+709
+32% +$756K ﹤0.01% 1370
2020
Q3 		$1.58M Buy
2,241
+72
+3% +$52.3K ﹤0.01% 1648
2020
Q2 		$1.52M Buy
2,169
+286
+15% +$165K ﹤0.01% 1622
2020
Q1 		$658K Buy
1,883
+141
+8% +$99.9K ﹤0.01% 1861
2019
Q4 		$1.1M Buy
+1,742
New +$852K ﹤0.01% 1874

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GEH
General Equity Holdings Brooklyn, New York $135M AUM 32.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

UBS AM's CDLX Position: Q1 2023 in Review

UBS AM sold out of Cardlytics (CDLX) in Q1 2023, closing a stake of 4,838 shares — an estimated $280K sold.

UBS AM first reported a position in CDLX in Q4 2019 and held it in 13 quarters. The position peaked at $4.82M in Q2 2021. 103 funds tracked by Wall St. Rank hold CDLX as of Q1 2023.

  • UBS AM reported no remaining Cardlytics position as of Q1 2023 after selling out during the quarter.
  • UBS AM sold 4,838 Cardlytics shares in Q1 2023, an estimated $280K.
  • UBS AM first reported a position in Cardlytics in Q4 2019 and held it in 13 quarters.
  • UBS AM's Cardlytics position peaked at $4.82M in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Cardlytics as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.